New class of drugs for the reversible inhibition of p... (ave severe disadvantages. As a result of...)

New class of drugs for the reversible inhibition of proteasomes

Date:11/22/2011

ave severe disadvantages. As a result of their high reactivity they attack other proteins, too, thereby damaging not only cancer cells but also other healthy cells.

The search for alternatives conducted by a group of scientists headed by Professor Michael Groll, who holds the Chair of Biochemistry in the Department of Chemistry at the TU Mnchen, in collaboration with Professor Robert Huber, Director Emeritus at the Max-Plank Institute of Biochemistry and Dr. Stefan Hillebrand from Bayer CropScience, has now borne fruit: In a high throughput screening, the scientists examined a substance library of 200,000 potential agents in their quest to identify proteasome inhibitors and they were successful. They identified a new structure with the so-called N-hydroxyurea motif, which reacts not only reversibly but above all specifically with the active nucleus of the proteasome. The structure inhibits the function of particular subunits of the protein complexes, which are catalytically active, and thus incapacitates the enzyme. Because of this property, the newly discovered hydroxyurea structures work more specifically than other proteasome inhibitors and are thus expected to lead to less severe adverse side effects.

The scientists were already familiar with the basic hydroxyurea structure, albeit in a completely different context. The substance in question is a derivative of the agent zileuton, which is used to treat asthma. Zileuton itself does not influence the proteasome, but its derivative, which had so far received little attention, does. "We have now found a completely new application for this previously known class of substances," explains Michael Groll. "This is of great advantage, because there are already clinical trials that give us first indications of how this class of substances behaves in the human body."

The initial structure originally discovered in the database inhibited the proteasome very specifically, but not terribly effectivel
'/>"/>

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technische Universitaet Muenchen
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
2. Scripps Research scientists identify new class of antimalarial compounds
3. Focus on testing hurts students in high school health classes
4. Cooking Class Benefits Kids in Many Ways
5. Classic Restless Legs Syndrome Not Linked to Parkinsons
6. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
7. Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study
8. Goldie Hawn to give public lecture on The Brain and the Optimistic Classroom at Aspen Brain Forum
9. Common class of pain drugs reduces severity of postpartum breast cancers
10. University of Leicester develops test for classifying force used in bottle stabbings
11. ASTRO announces 2011 Fellows class

Post Your Comments:

Related Image:

New class of drugs for the reversible inhibition of proteasomes

(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...

(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...

(Date:5/18/2013)... Assisted living and retirement communities have ... comfort of their residents. Systems Technologies is well-acquainted ... effective and cost-efficient solution – VisionLink Wireless Nurse ... communications solution that helps nurses provide the highest ... privacy. , The VisionLink nurse call ...

(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...

(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...

Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New research identifies practice changes to improve value and quality of GI procedures 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3

[0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New research identifies practice changes to improve value and quality of GI procedures [0] VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities [0] Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation [0] Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets

... of phosphate in the blood are more likely to ... key indicator of atherosclerosis and future cardiovascular disease risk, ... the Journal of the American Society of Nephrology ... unidentified and modifiable cardiovascular risk factor, and could help ...

... Diluted Share, FARMINGDALE, N.Y., Nov. 13 Misonix, ... ultrasonic medical device,technology, which in Europe is used for ... conditions, today reported financial,results for its fiscal year 2009 ... President and Chief Executive Officer, and Richard,Zaremba, Senior VP ...

... Savings Over 70% Are Easily Found with Free, ... 13 With one-quarter of,Americans paying out-of-pocket to ... in coming months, PharmacyChecker.com published "Safe,Strategies for Drug ... By,shopping online at verified pharmacies in the U.S., ...

... S.C., Nov. 13 Companion Benefit,Alternatives Inc. ... and substance,abuse treatment benefits in South Carolina, ... among 23 finalists in URAC,s prestigious,Best Practices ... Awards,competition., URAC, a leading independent accrediting ...

... more stringent standards that require nurses to submit fingerprints and undergo ... years. RecordGone.com helps nurses expunge their criminal records, making it ... , ... Costa Mesa, CA (PRWEB) November 13, 2008 ...

... gender, race and/or marital status can factor into the ... gender is the most significant factor impacting overall survival, ... Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, ... National Cancer Institute, in 2008 approximately 215,020 new cases ...

High-normal phosphate levels linked to early atherosclerosis Misonix Reports First Quarter Fiscal Year 2009 Financial Results PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication CBA's Innovative Program for Managing Depression Earns National Recognition RecordGone.com Helps California Nurses Expunge Criminal Records to Meet More Stringent Licensing Standards Gender is key factor in determining overall survival of lung cancer patients

(Date:5/17/2013)... , May 17, 2013 Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...

(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013. ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...

(Date:5/16/2013)... Nektar Therapeutics, (Nasdaq: NKTR ) President and ... is scheduled to present at the upcoming 2013 UBS Global ... the Sheraton New York Hotel on Tuesday, May 21, 2013 ... be accessible via a Webcast through a link posted in ... http://www.nektar.com . This Webcast will be available for replay ...

Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2

[0] Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference [0] Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results [0] Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

... ,, NEW YORK , Aug. 2 Reportlinker.com announces that a new ... , , ... , , ... This research service ...

... July 31 , Massachusetts lawmakers passed legislation that includes limited ... , , ... mandatory minimum sentences at county Houses of Correction will have greater access ... on did not include two reforms previously endorsed by the Senate: allowing ...

Cached Medicine Technology:Western European Market for Image-guided and Robot-assisted Surgery 2 Western European Market for Image-guided and Robot-assisted Surgery 3 Western European Market for Image-guided and Robot-assisted Surgery 4 Western European Market for Image-guided and Robot-assisted Surgery 5 Western European Market for Image-guided and Robot-assisted Surgery 6 Western European Market for Image-guided and Robot-assisted Surgery 7 Western European Market for Image-guided and Robot-assisted Surgery 8 FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2

Western European Market for Image-guided and Robot-assisted Surgery FAMM Applauds Massachusetts Legislature for Sentencing Reforms

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Allergen, Occupational, Phthalic Anhydride Allergen, Occupational, Isocyanate TDI Allergen, Occupational, Ethylene Oxide Allergen, Mites, Euroglyphus maynei